{"schema_version":"secwatch.filing_event.v1","accession":"0001745020-23-000073","form_type":"8-K","ticker":null,"cik":"0001745020","company_name":"Theseus Pharmaceuticals, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.291584+00:00","generated_at":"2026-06-08T05:18:18.099984+00:00","sec_items":["2.02","2.05","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Theseus Pharma lays off 72% of staff, explores strategic alternatives; cash $225.4M","bullets":["Workforce reduction of ~72% (26 employees, including R&D President); severance costs ~$5.5M in Q4 2023.","Process to explore strategic alternatives including potential sale of company or assets to maximize shareholder value.","Cash, cash equivalents, and marketable securities total $225.4M as of September 30, 2023.","President R&D William Shakespeare terminated without cause; receives $0.5M severance, accelerated equity vesting, consulting role through June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001745020-23-000073","json":"https://secwatch.observer/filing/0001745020-23-000073.json","markdown":"https://secwatch.observer/filing/0001745020-23-000073.md","text":"https://secwatch.observer/filing/0001745020-23-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745020/000174502023000073/0001745020-23-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745020/000174502023000073/thrx-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:18:18.099984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76a480871a","claim":"William C. Shakespeare, Ph.D. was terminated as President of Research and Development at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"the Company terminated the employment of William C. Shakespeare, Ph.D. as President of Research and Development of the Company, effective as of November 9, 2023 (the “Separation Date”), without cause.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000174502023000073/0001745020-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President of Research and Development"}],"fact_type":"executive_change"},{"claim_id":"fcb225481a2e47641a8d255060eaf8bb2455356b","claim":"Theseus Pharmaceuticals, Inc. announced a restructuring with charges of $5.5 million (26 full-time employees, or approximately 72% of the Company’s then-current employee base).","evidence_excerpt":"employee’s entering into an effective separation agreement, which includes a general release of claims against the Company. The reduction of workforce is expected to result in $5.5 million in severance costs. The incremental costs are expected to be incurred in the fourth quarter of 2023. --- EX-99.1 (EX-99.1) --- Theseus Pharmaceuticals Announces Process to","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000174502023000073/0001745020-23-000073-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$5.5 million"},{"label":"Headcount","value":"26 full-time employees, or approximately 72% of the Company’s then-current employee base"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}